A Delaware jury has ordered Gilead Sciences to pay $2.54 billion in damages to Merck for infringing a patent related to hepatitis C treatment. It is the largest-ever patent damages award
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
National groups for the UK and the Netherlands have flagged concerns with the choice of venue, following a formal complaint from Australia’s national group